Large-scale study links ketamine to lower risk of suicidal ideation in depression patients
A recent study published in Translational Psychiatry found that ketamine, a medication typically used as an anesthetic, may significantly reduce suicidal thoughts in individuals with recurrent major depressive disorder (MDD) compared to those prescribed more common antidepressants. The research shows that those prescribed ketamine had a lower risk of developing suicidal ideation over the short and long term, up to 270 days following treatment, compared to patients taking other antidepressants. Major depressive disorder is a widespread condition that often recurs, meaning individuals who experience one episode of depression are highly likely to have future episodes. Recurrent MDD can be particularly challenging to treat, and many patients do not respond to traditional antidepressants. Suicidal ideation, or thoughts of suicide, is common among those with MDD and poses a major public health concern, as suicide remains one of the leading causes of death in the United States. In recent years, ketamine has emerged as a promising treatment option for people with treatment-resistant depression. Research suggests that it can provide rapid relief from depressive symptoms, including suicidal ideation. …